Medicare prescriptions for the anti-obesity medication Wegovy surged 598% in the six months following a federal policy shift that allowed coverage for heart disease prevention. Despite this increase, new research from the USC Schaeffer Center for Health Policy & Economics reveals that less than 1% of the estimated 3.6 million eligible beneficiaries have accessed the drug, citing barriers such as high costs and limited provider awareness.
The Impact of Expanded FDA and Medicare Policy
In March 2024, Medicare clarified that Part D plans could cover Wegovy for patients with obesity and heart disease, following an expanded FDA approval. This policy change acted as a catalyst for widespread uptake. According to the USC Schaeffer Center, total fills for Wegovy across all coverage types—including Medicare, Medicaid, private insurance, and cash-pay—rose 136% in the six months following the announcement.
The data suggests that the cardiovascular indication was the primary driver for this growth, accounting for approximately 593,000 additional prescriptions. While Medicare beneficiaries led the charge with a 598% increase in fills, the overall reach remains narrow relative to the total eligible population.
The rapid growth in Wegovy prescriptions has significantly outpaced other GLP-1 medications that share the same active ingredient, semaglutide. Researchers attribute this specifically to the new cardiovascular health approval.
Barriers to Widespread GLP-1 Access
Why are fewer than 1% of eligible beneficiaries receiving treatment? The USC Schaeffer Center study points to a combination of systemic hurdles. Part D plans have shown hesitation in adding these high-cost medications to their formularies, creating a bottleneck for patients. Even when the drug is covered, patients often face substantial cost-sharing requirements or other restrictions on use.
Furthermore, there is a clear knowledge gap. Many healthcare providers may have had limited awareness of the changes, which limits the number of prescriptions being written. Christopher Scannell, a nonresident scholar at the USC Schaeffer Institute and the study’s first author, noted that while the policy change is a step forward, the healthcare system still struggles to ensure that patients can both access and afford these medications as clinical indications broaden.
Future Trends: The Medicare GLP-1 Bridge and Beyond
To address the current access gap, the federal government launched the “Medicare GLP-1 Bridge” pilot program this month. This initiative aims to expand access to GLP-1s for weight loss, though it operates on a temporary basis. The program is currently scheduled to expire after 2027, creating uncertainty regarding its long-term viability. Many health insurers have balked at a longer-term program, citing the financial burden of shifting these costs onto them.
However, the trend toward broader coverage is likely to continue through non-obesity pathways. Medicare continues to permit coverage for Wegovy and other GLP-1s when used for FDA-approved conditions beyond weight loss. These include:
- MASH: A serious liver disease for which Wegovy has gained approval.
- Obstructive Sleep Apnea: A condition for which other GLP-1s have been approved.
- Chronic Kidney Disease: A condition for which other GLP-1s have been approved.
If you are a Medicare beneficiary, check your specific Part D plan’s formulary for updates regarding cardiovascular or secondary condition coverage for GLP-1s, as coverage can vary significantly between providers.
Frequently Asked Questions
Does Medicare cover Wegovy for weight loss?
Medicare is generally prohibited from paying for drugs to treat obesity. However, it does cover Wegovy if it is prescribed to reduce the risk of heart complications in beneficiaries who also have obesity and heart disease.
Why is the uptake for Wegovy so low among Medicare beneficiaries?
Research indicates that high cost-sharing, restrictive formulary policies by Part D plans, and limited awareness among providers are the primary factors preventing wider adoption, despite millions of beneficiaries being clinically eligible.
What is the Medicare GLP-1 Bridge program?
It is a temporary, federally funded pilot program launched to expand access to GLP-1 medications. It is set to conclude after 2027.
Are other GLP-1 medications covered by Medicare?
Yes, Medicare covers GLP-1s for the treatment of Type 2 diabetes. Coverage for other conditions, such as sleep apnea or kidney disease, depends on specific FDA approvals and individual plan policies.
Have you or a family member encountered difficulty accessing GLP-1 medications through Medicare? Share your experience in the comments below or subscribe to our newsletter for the latest updates on healthcare policy changes.